A Hep C Love Triangle

Vertex Pharmaceuticals (Nasdaq: VRTX  ) has found not one but two new beaus, although it's keeping the relationships casual.

For a disease like hepatitis C where combinations will be the new norm, getting in bed with as many players as possible is critical. Assuming of course you're not Gilead Sciences (Nasdaq: GILD  ) or Abbott Labs (NYSE: ABT  ) , which have all the drugs they need to make a decent combination on their own.

Vertex doesn't. It has VX-135, which looks like it might be a decent nuc, but it needs to combine VX-135 with other drugs to reach the high cure rates Gilead and Abbott have put up.

Enter Johnson & Johnson (NYSE: JNJ  ) and GlaxoSmithKline (NYSE: GSK  ) . In separate deals, Vertex announced that it'll test VX-135 with Johnson & Johnson's simeprevir  and Glaxo's GSK2336805.

Simeprevir is a protease inhibitor that's in the same class as Vertex's already-approved Incivek. Vertex is hedging its bet with this partnership because it's generally assumed that the second-generation protease inhibitors will be better than Incivek and Merck's (NYSE: MRK  ) Victrelis.

Johnson & Johnson and Vertex will split the cost of the phase 2 trial scheduled to start early next year. Once they see that data, they'll presumably figure out a development plan because the current deal doesn't extend beyond the proof-of-concept study.

The deal with Glaxo has a similar structure. The companies will split the cost of a phase 2 proof-of-concept study combining VX-135 and NS5A inhibitor GSK2336805 with or without ribavirin, a generic drug. That pair is shooting for starting that trial early next year.

Left out in the cold is Bristol-Myers Squibb (NYSE: BMY  ) , which also has an NS5A inhibitor called daclatasvir. The drug worked well with Gilead's nuc GS-7977, so it's curious that Vertex went with Glaxo's NS5A inhibitor rather than daclatasvir.

Of course, considering that the deals seem pretty casual, Vertex might be able to partner with Bristol as well.

Love square, anyone?

While the hepatitis C players jockey for position, these three companies are setting themselves up to dominate retail. Find out what they are and why Fool analysts like them so much in the new free report, "3 Companies Ready to Rule Retail." Get your copy for free by clicking here now.

Fool contributor Brian Orelli has no positions in the stocks mentioned above. The Motley Fool owns shares of Gilead, GlaxoSmithKline, and Johnson & Johnson. Motley Fool newsletter services recommend Gilead, GlaxoSmithKline, Johnson & Johnson, and Vertex Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2089836, ~/Articles/ArticleHandler.aspx, 4/17/2014 6:51:35 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement